Welcome to our dedicated page for Medicinova SEC filings (Ticker: MNOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for MediciNova, Inc. (MNOV), a clinical-stage biopharmaceutical company developing small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. As a Delaware corporation with common stock listed on Nasdaq, MediciNova files registration statements, annual and quarterly reports, current reports, and proxy materials that describe its business and risks in detail.
In its registration statement on Form S-1, MediciNova outlines its focus on MN-166 (ibudilast) for neurological and other disorders and MN-001 (tipelukast) for fibrotic and metabolic disorders, along with its commercial focus on the U.S. market. The S-1 also describes capital-raising arrangements, such as a Standby Equity Purchase Agreement that allows the company to sell shares to a specified investor over time.
Current reports on Form 8-K include items such as the results of the annual meeting of stockholders, where shareholders vote on director elections, auditor ratification, and advisory resolutions on executive compensation and the frequency of future advisory votes. These filings provide insight into MediciNova’s corporate governance and shareholder decisions.
On Stock Titan, MediciNova’s SEC filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, so readers can quickly understand how a filing relates to the company’s pipeline, financing arrangements, or governance. Users can review registration statements, 8-Ks, and other reports in one place and use the AI summaries to focus on sections most relevant to their analysis of MNOV.
MediciNova, Inc. has called its 2026 Annual Meeting for June 23, 2026 in La Jolla, California. Stockholders will vote on electing two Class I directors, ratifying BDO USA, P.C. as auditor, and approving a major increase in authorized common stock.
The company proposes amending its Restated Certificate of Incorporation to raise authorized common shares from 100,000,000 to 247,000,000, while keeping preferred stock at 3,000,000 shares. As of April 24, 2026, 49,221,246 common shares were outstanding, with additional shares reserved for equity plans.
MediciNova, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on June 23, 2026 in La Jolla, California. The notice/ proxy materials are expected to be mailed on or around April [ ], 2026 and the record date for voting is April 24, 2026.
Stockholders will vote to (1) elect two Class I directors (Hideki Nagao and Nicole Lemerond), (2) ratify BDO USA, P.C. as independent auditors for fiscal 2026, (3) approve an increase in authorized common stock from 100,000,000 to 247,000,000 shares, (4) approve adjournment authority to permit further solicitation, and (5) transact other business properly brought before the meeting.
MediciNova, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held June 23, 2026 at 1:00 p.m. PDT in La Jolla, California. Stockholders of record as of April 24, 2026 may vote on: election of two Class I directors; ratification of BDO USA, P.C. as independent auditors; an amendment to increase authorized common stock from 100,000,000 to 247,000,000 shares; and a proposal to permit adjournment for further solicitation. The proxy materials and the 2025 Annual Report will be furnished primarily via the Internet and are available at the listed proxy website.
MediciNova, Inc. files its annual report describing a late‑stage biopharmaceutical pipeline built around two lead drug candidates, MN‑166 (ibudilast) and MN‑001 (tipelukast). The company focuses on serious diseases with high unmet need, including progressive multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, degenerative cervical myelopathy, ARDS in COVID‑19, and NASH/NAFLD with metabolic disorders.
MN‑166 has Fast Track designations in progressive MS and ALS and Orphan‑Drug designations in ALS and glioblastoma, supported by multiple Phase 2 and Phase 2b/3 trials and extensive preclinical data. MN‑001 targets fibrotic and metabolic liver disease, with Fast Track for NASH with fibrosis and positive Phase 2 and preclinical results in triglyceride reduction and anti‑fibrotic effects. The report notes continued operating losses, no approved commercial products, dependence on external manufacturing and strategic partners, and significant clinical, regulatory, and market competition risks.
MediciNova furnished preliminary, unaudited results for the year ended December 31, 2025 via its Tanshin report filed with the Tokyo Stock Exchange. Revenue was $0.41M, all from a Mayo Foundation ALS research agreement, versus no revenue in 2024.
The company recorded an operating loss of $13.28M and a net loss of $12.00M, slightly higher than 2024, as research and development held around $7.2M and general and administrative expenses rose to $6.16M including Standby Equity Purchase Agreement fees. Basic and diluted net loss per share was $0.24.
Cash and cash equivalents were $30.81M as of December 31, 2025, with operating cash outflow of $9.81M. MediciNova expects 2026 operating expenses of about $16.2M (an 18% increase) and believes current cash can fund operations at least through the end of February 2027, supported by existing ATM programs and a $30.0M standby equity facility.
MediciNova Inc.'s Chief Medical Officer, Matsuda Kazuko, reported a performance-based equity award on Form 4. On January 16, 2026, the officer acquired an employee stock option to buy 350,000 shares of common stock at an exercise price of $2.10 per share, expiring on January 6, 2035. According to the disclosure, this option was originally granted on January 7, 2025 and was tied to performance criteria for the fiscal year ended December 31, 2025. Those criteria were met, resulting in full vesting of the 350,000-share option, which is now directly owned and fully exercisable.
MediciNova Inc. reported an insider equity award for its President and CEO, Yuichi Iwaki. On January 16, 2026, he acquired an employee stock option covering 450,000 shares of common stock at a $2.10 exercise price per share. These options were originally granted on January 7, 2025 and were tied to performance criteria for the fiscal year ended December 31, 2025. The filing states that the 2025 performance criteria were met, resulting in the full vesting of the option. After this transaction, Iwaki holds 450,000 derivative securities directly, with the options exercisable from January 16, 2026 and expiring on January 6, 2035.
MediciNova (MNOV) filed its Q3 2025 10‑Q, reporting modest service revenue and a wider operating loss. Revenue was $123,319, reflecting work under its Mayo agreement for ALS research. Net loss was $3,050,373, or $0.06 per share. Operating expenses were $3,504,317, with research, development and patents at $1,582,975 and general and administrative at $1,806,070, the latter elevated by Standby Equity Purchase Agreement (SEPA) fees.
Cash and cash equivalents were $32,562,612, down from $40,359,738 at year‑end, as operating cash outflows totaled $7,793,264 for the nine months. Stockholders’ equity was $43,964,756. The company recorded $521,899 of deferred revenue from Mayo and recognized $257,918 of revenue year‑to‑date. Interest income declined to $340,850 in the quarter as cash balances fell.
Liquidity and capital access: management states cash is sufficient to fund operations at least through November 2026. In July, MediciNova established a $30.0 million SEPA with Yorkville (97% of the lowest three‑day VWAP pricing mechanism; 19.99% Exchange Cap at 9,804,345 shares), and also maintains a $75.0 million ATM; no shares were sold under either program year‑to‑date. Shares outstanding were 49,046,246 as of November 10, 2025.
MediciNova, Inc. (MNOV) files an S-1 describing its clinical-stage pipeline centered on MN-166 (ibudilast) and MN-001 (tipelukast) and a financing arrangement with YA. MN-166 showed positive Phase 2b SPRINT-MS results including a 48% reduction in whole brain atrophy versus placebo (p=0.04) and a 26% reduction in risk of confirmed disability progression (HR=0.74); results were published in the New England Journal of Medicine. Multiple additional MN-166 programs reported milestones: positive Phase 2 COVID-19 ARDS topline results (statistical significance on respiratory-failure-free and hospital discharge endpoints; two placebo deaths, none on drug), IND and Orphan Drug for glioblastoma with Phase 2 enrollment completed, and ongoing/additional addiction and ophthalmic studies. MN-001 holds Fast Track designation for NASH with fibrosis and has completed/initiated several Phase 2 studies with positive subgroup and preclinical findings.
On financing, the company may sell up to $30.0 million of common stock to YA under a Purchase Agreement (registration to cover up to 25,000,000 shares). If all 25,000,000 shares were outstanding, they would represent ~51.0% of total shares and ~52.5% of non-affiliate shares (as of Aug 11, 2025). The agreement also includes an Exchange Cap limiting issuance to 9,804,345 shares (~19.99%) absent shareholder approval or price conditions. The filing lists exhibits, prior SEC filings, and signatures.